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Abstract: Objectives: Hypertension and type 2 diabetes mellitus comorbidity (HDC) is common,
which confers a higher risk of cardiovascular disease than the presence of either condition alone.
Describing the underlying glycomic changes of immunoglobulin G (IgG) that predispose individuals
to HDC may help develop novel protective immune-targeted and anti-inflammatory therapies. Therefore, we investigated glycosylation changes of IgG associated with HDC. Methods: The IgG N-glycan
profiles of 883 plasma samples from the three northwestern Chinese Muslim ethnic minorities and
the Han Chinese were analyzed by ultra-performance liquid chromatography instrument. Results:
We found that 12 and six IgG N-glycan traits showed significant associations with HDC in the
Chinese Muslim ethnic minorities and the Han Chinese, respectively, after adjustment for potential
confounders and false discovery rate. Adding the IgG N-glycan traits to the baseline models, the area
under the receiver operating characteristic curves (AUCs) of the combined models differentiating
HDC from hypertension (HTN), type 2 diabetes mellitus (T2DM), and healthy individuals were
0.717, 0.747, and 0.786 in the pooled samples of Chinese Muslim ethnic minorities, and 0.828, 0.689,
and 0.901 in the Han Chinese, respectively, showing improved discriminating performance than
both the baseline models and the glycan-based models. Conclusion: Altered IgG N-glycan profiles
were shown to associate with HDC, suggesting the involvement of inflammatory processes of IgG
glycosylation. The alterations of IgG N-glycome, illustrated here for the first time in HDC, demonstrate a biomarker potential, which may shed light on future studies investigating their potential for
monitoring or preventing the progression from HTN or T2DM towards HDC.

This article is an open access article
distributed under the terms and

Keywords: hypertension and type 2 diabetes mellitus comorbidity; IgG; N-glycosylation; biomarkers

conditions of the Creative Commons
Attribution (CC BY) license (https://
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1. Introduction
Hypertension (HTN) is one of the leading modifiable risk factors for morbidity and
mortality of cardiovascular disease (CVD) worldwide [1]. Likewise, type 2 diabetes mellitus (T2DM) has become one of the global disease burdens [2]. HTN and T2DM are closely
interlinked due to similar risk factors including obesity, dyslipidemia, insulin resistance,
endothelial dysfunction, vascular inflammation, atherosclerosis, and sequential inappropriate activation of renin-angiotensin system, etc. [3,4]. Previous studies have shown that
hypertension is at least twice as frequent in patients with diabetes compared with those
who do not have diabetes [5]. Accordingly, a considerable portion of the world population
undergoes coexistent T2DM and HTN, which increases the risk of CVD and renal failure
in individuals [6]. Compared with the normotensive non-diabetic individuals, patients
with HTN and T2DM comorbidity (HDC) have a four-fold increased risk of CVD [7]. The
number of patients diagnosed with HTN and T2DM comorbidity (HDC) is on the rise,
resulting in increased medical expenses and resource utilization [8]. Thus, further studies
of biomarkers for monitoring and preventing the progression from HTN or T2DM towards
HDC are timely and called for.
The glycan attachment to individual proteins is driven by specific enzymes and plays
an indispensable role in almost all physiological processes [9]. In general, N-glycome constructed in healthy individuals is fairly stable but can vary due to pathological conditions,
especially during inflammation [10]. Altered glycosylation pathways can have significant
effects on protein structure and function that occur during the transition from healthy
to diseased states. Due to the absence of the genetic template and the lack of stringency
within the biosynthetic pathway, the glycan structures of individuals are influenced by the
intricate interplay of genetic polymorphisms and environmental factors [11]. Therefore, it is
warranted to elucidate the role of altered glycome composition in the pathogenic immune
response and to analyze the possibility of using N-glycosylation as a latent predictor for
the development of multifactorial diseases, such as HDC.
As the most abundant antibody in human blood, immunoglobulin G (IgG) regulates
systemic inflammation balance at multiple levels, and its function is largely influenced
by glycosylation. It has been shown that the pro- and anti-inflammatory activities of IgG
could no longer be demonstrated if N-glycans are completely removed [12]. Aberrant IgG
N-glycosylation has also been demonstrated to be involved in the pathogenesis such as
aging [13], HTN [14], and T2DM [15,16], which are relevant risk factors contributing to
HDC. These observations make us speculate that changes of IgG N-glycosylation may
be related to the pathogenesis of HDC by regulating inflammation. Understanding the
underlying altered IgG N-glycosylation profiles that predispose individuals to HDC may
help to develop novel protective immune-targeted and anti-inflammatory therapies and/or
prevention approaches. However, the associations between IgG N-glycans and HDC have
not been described in current literature.
There are 55 officially recognized ethnic minority groups within China in addition to
Han majority (which constitute about 91.9% of the total population). The population size
of Han Chinese and Chinese ethnic minorities are 1286.3 and 125.5 million, respectively
(according to the seventh national census statistics of China conducted in 2020). The
genetic background, culture, socioeconomic conditions, climate, geographical features,
lifestyle, and dietary habit are substantially different between Han Chinese and other ethnic
minorities. The Kirgiz (KGZ), Tajik (TJK), and Uygur (UIG) are three Chinese Muslim
ethnic minorities, with a total population size of 11.94 million, inhabiting the Xinjiang
Uygur Autonomous Region, the northwestern frontier of China, for generations, without
intermarry with other ethnic groups [17]. These Chinese Muslim minorities share relatively
similar lifestyles, diet-related habits, living environment, culture, and genetic backgrounds,
thereby are well-defined isolated populations with substantial ancestry contribution from
Western Eurasian people [18,19]. The prevalence of HTN and T2DM in the northwestern
Chinese minority populations is on the rise and relatively higher than that in the Han
Chinese, the majority ethnic group in China [20,21]. Investigating the IgG N-glycan profiles
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of ethnic groups with different prevalence of HTN and T2DM could shed light on the
potential population-specific and/or general IgG N-glycan patterns and their relevance to
the pathogenesis of HDC.
In this study, we investigated the changes in IgG N-glycosylation profiles associated
with HDC and their biomarker potential for distinguishing HDC from HTN, T2DM, and
healthy individuals in the aforementioned populations. This work could further increase
our understanding of HDC pathophysiology and may shed light on future studies investigating their potential for monitoring or preventing the progression from HTN or T2DM
towards HDC.
2. Materials and Methods
2.1. Subjects
The participants from the three northwestern Chinese ethnic minorities (KGZ, TJK, and
UIG) were recruited, and their demographic characteristics (gender, age, ethnicity, levels
of education, occupation, and urban/rural residence) and anthropometric measurements
(height, weight, body mass index [BMI], and blood pressure), as well as blood samples, were
collected. All the Muslim participants were recruited from the isolated underdeveloped
rural areas (Halajun town, Tagan town, and Minfeng town) of Xinjiang, China, where
the respective Muslim minority “exclusively” inhabit for generations without co-resident
Han or other ethnic groups, with either primary or secondary education. The occupations
of all the UIG participants were farmers and of all the KGZ and TJK participants were
herdsmen. A total of 484 samples from 165 KGZ, 146 TJK, and 173 UIG were included in
this study, composed of 67 HDC, 183 HTN, 51 T2DM, and 183 healthy individuals (median
ages for the four health condition groups: 63, 59, 54, and 51 years). The participants met the
following inclusion criteria: (1) Over 18 years old; (2) self-reported the KGZ, TJK, or UIG
ethnicity without intermarriage history with other ethnic groups within at least the past
three generations. Individuals were excluded based on the following criteria: (1) Pregnant
or lactating women; (2) history of severe hepatic, nephritic and autoimmune disease; and
(3) diagnosis of diseases of mental illness or infectious disease.
In this study, a total of 399 Han Chinese participants from a community-based survey
in Beijing were also included, composed of 72 HDC, 112 HTN, 50 T2DM, and 165 healthy
controls (median ages for the four health condition groups: 66, 49, 54, and 46 years).
The demographic characteristics, anthropometric measurements, and blood samples of
Han Chinese population were collected in a cross-sectional study conducted in 2012, as
described previously [13].
All 883 participants included in this study have signed written informed consent.
The study was approved by the local community leaders and the Ethics Committee of
Capital Medical University, Beijing, China (No. 2015SY21 and 2009SY16) and adhered to
the principles of the Declaration of Helsinki.
2.2. Diagnostic Criteria
HTN was defined as an average systolic blood pressure (SBP) ≥ 140 mmHg and/or an
average diastolic blood pressure (DBP) ≥ 90 mmHg, according to the Chinese guidelines
for the prevention and treatment of HTN in adults [22]. Peripheral blood samples of
the participants for analyses of biochemical indicators (fasting plasma glucose and blood
lipids) and IgG N-glycan profiles were collected using EDTA anti-coagulated tube after an
overnight fast. The diagnosis of T2DM was based on fasting blood glucose ≥ 7.0 mmol/L in
this study, according to World Health Organization (WHO) Criteria [23]. HDC was defined
as the co-existence of HTN and T2DM [24]. Dyslipidemia was defined as total cholesterol
(TC) ≥ 6.2 mmol/L, triglycerides (TG) ≥ 2.3 mmol/L, low-density lipoprotein cholesterol (LDL) ≥ 4.1 mmol/L, or high-density lipoprotein cholesterol (HDL) < 1.0 mmol/L,
according to the Guidelines for Prevention and Treatment of Dyslipidemia in Adults in
China [25].
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2.3. Analysis of IgG N-glycosylation
IgG was isolated from plasma samples from all participants using 96-well protein
G monolithic plates, and N-linked glycans were released and labeled as described previously [26]. In brief, the isolated IgG was eluted from protein G with 1 mL of 0.1 M formic
acid and instantly neutralized with 1 M ammonium bicarbonate. Then, IgG N-glycans
were released using PNGase F, labeled with 2-aminobenzamide and purified with 96%
acetonitrile and ultrapure water to remove proteins, salts and excess of reagents from
deglycosylation and fluorescent labeling reaction. In the end, IgG N-glycans were analyzed
by hydrophilic interaction liquid chromatography (HILIC) using ultra-performance liquid
chromatography (UPLC) instrument as described previously [27].
In total, 24 chromatographic peaks, (i.e., IgG glycan peaks (GPs, GP1–GP24)) were
measured and the amount of glycans in each peak was expressed as percentage of total
integrated area [15], and the detailed structures of the N-glycan peaks were shown in
Table S1. The 54 derived glycan traits (DGs, DG1–DG54) were calculated from the directly
measured GPs [28]. These DGs were used to describe the relative abundance of galactosylation, sialylation, bisecting N-acetylglucosamine (GlcNAc), and core fucosylation. To
remove the experimental variation from measurements, normalization and batch correction
were conducted on the UPLC measured glycan data [29]. Therefore, the measurements
were comparable across all samples.
2.4. Statistical Analysis
Based on our previous publications, in which the correlation coefficients of the relationship between the sialylated glycans (i.e., IgG 4 G1S (that is, Galactose and Sialic
acid) and monosialylated glycan, respectively) and SBP in the Chinese Muslim ethnic
minority (Kazakh) and the Han Chinese were of a similar magnitude: −0.373 and −0.372,
respectively [30,31]. With 75% power and a 0.05 two-sided significance level, the required sample size is estimated to be 48 participants for each of the four health condition groups (i.e., HDC, HTN, T2DM, and healthy individuals) using StatsToDo (http:
//www.statstodo.com/SSizCorr_Pgm.php; accessed on 9 October 2020). The data from
the three Chinese Muslim ethnic minorities with similar genetic and environmental backgrounds were pooled together for the statistical analysis, given that the sample size of the
respective four health condition groups of the individual Chinese Muslim ethnic minority
is insufficient.
Normality distributions of all glycan traits were double-checked by using the Kolmogorov–
Smirnov test and Shapiro–Wilk test. When the continuous variable conformed to the normality
distribution, means together with standard deviations were used in descriptive statistics.
Otherwise, medians together with the interquartile ranges were used. The Chi-square test
was applied to investigate the differences in categorical variables. Since the majority of the
IgG N-glycan traits were not normally distributed, the Kruskal–Wallis test was conducted to
determine the differences of directly measured and derived IgG N-glycan traits among the
HDC, HTN, T2DM, and healthy controls.
The IgG glycosylation features of HDC may combine the IgG glycosylation features of both HTN and T2DM, thus a Venn diagram was constructed to illustrate shared
IgG N-glycan features between the four health condition groups using online software
(http://bioinformatics.psb.ugent.be/webtools/Venn/; accessed on 17 April 2021). The associations between HDC and IgG N-glycan traits were assessed through logistic regression
analysis, with the IgG N-glycan traits as independent variables, adjusted for potential
confounders (i.e., age, gender, ethnicity, BMI, and dyslipidemia). Given the potential
internal associations among IgG N-glycan traits, which could induce multicollinearity in
the statistical models, the least absolute shrinkage and selection operator (LASSO) method
was conducted to reduce dimension before constructing the logistic regression models.
To evaluate differences in IgG N-glycan traits of different health conditions in the three
Chinese Muslim minorities pooled samples and Han Chinese samples, the IgG N-glycan
traits screened by the LASSO method were included to construct logistic regression models
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for HDC versus HTN, HDC versus T2DM, and HDC versus healthy controls, respectively.
Three types of logistic classification models were applied: (1) The baseline models included
age, gender, ethnicity, BMI, and dyslipidemia as the covariates; (2) the glycan-based
models included the screened IgG N-glycan traits as the covariates; and (3) the combined
models incorporated the screened IgG N-glycan traits on top of the covariates included
in the baseline models. The prediction error of the five-fold cross-validation procedure
was used to assess the performance of the discriminant models (R package “boot”) [32].
The discriminant ability of the models in delineating the HDC from the HTN, T2DM,
and healthy individuals was evaluated by receiver operating characteristic (ROC) curve
analysis (R package “pROC”).
Data were analyzed and visualized using SAS (Version 9.4) and R packages (Version 4.0.4). For the logistic regression analysis, the Benjamini–Hochberg procedure was
used to control the false discovery rate (FDR) [33]. All analyses were two-sided, and
statistical significance was set at p < 0.05. Bonferroni adjustment was used for multiple
comparisons among the four health condition groups to control familywise error rate
(FWER) in a very stringent criterion and to compute the adjusted p values by directly adjust
the significance level as α0 = α/m (i.e., the number of simultaneously tested hypotheses).
Thus, p < 0.05/6 (0.0083) was considered to be statistical significance in the comparative
analysis of demographic and biochemical characteristics, and the levels of IgG N-glycans
between the groups.
3. Results
3.1. Demographic and Biochemical Characteristics
A total of 883 participants (484 Chinese Muslim minorities and 399 Han Chinese) were
analyzed in this study. Demographic and biochemical characteristics of the HDC, HTN,
T2DM, and healthy individuals for the Chinese Muslim ethnic minorities and those for the
Han Chinese are shown separately (Table S2) and pooled together in Table 1. In the pooling
of the Chinese Muslim ethnic minorities, the age significantly differed in HDC compared
to T2DM and healthy controls, and the SBP and DBP were significantly higher in the HDC
group than those in both T2DM and healthy individuals, and the FBG was higher in the
HDC than that in both the HTN and healthy individuals. In the Han Chinese individuals,
the age, gender, BMI, SBP, DBP, TC, TG, LDL, FBG, and dyslipidemia significantly differed
among the four health condition groups (i.e., HDC, HTN, T2DM, and healthy controls).
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Table 1. Demographic and biochemical characteristics of the study subjects in the pooled samples from Chinese Muslim ethnic minorities and the Han Chinese samples.
Pooling of Chinese Muslim Ethnic Minorities
Variables
Gender
(male%)
Age (years)
BMI (kg/m2 )
SBP (mmHg)
DBP (mmHg)
FBG
(mmol/L)
TC (mmol/L)
TG (mmol/L)
HDL
(mmol/L)
LDL
(mmol/L)
Dyslipidemia
(%)

Han Chinese

HDC
(n = 67)

HTN
(n = 183)

T2DM
(n = 51)

Controls
(n = 183)

p*

HDC
(n = 72)

HTN
(n = 112)

T2DM
(n = 50)

Controls
(n = 165)

p*

37 (55.22%)

71 (38.80%)

16 (31.37%)

76 (41.53%)

4.80 × 10−2

37 (51.39%)

58 (50.43%)

23 (46.00%)

26 (15.76%) #

<1.00 × 10−3

63 (54, 69)

59 (48, 67)

54 (43, 68)

51 (40, 61) $,#

<1.00 × 10−3

<1.00 × 10−3

27.04 ± 4.73

26.27 ± 4.39

25.85 ± 4.69

54 (46, 73)
24.22 (21.73,
27.53)
116.00 ± 16.16
71.92 ± 10.14

46 (42, 50) &,#

26.23 ± 4.52

49 (43, 54)
25.68 (23.84,
27.76)
132.77 ± 10.53
93.13 ± 6.01

23.11 (21.57, 25.08) #

<1.00 × 10−3

151.03 ± 21.47
93.78 ± 13.42

147.13 ± 21.72
91.82 ± 14.06

116.27 ± 9.69
72.84 ± 8.10

115.35 ± 10.62
73.02 ± 8.93 $,#

<1.00 ×
<1.00 × 10−3

66 (49, 76)
24.97 (23.03,
27.04)
148.88 ± 15.77
83.67 ± 10.31

7.40 (6.70, 8.10)

5.30 (5.00, 5.80)

7.00 (6.70, 7.80)

5.20 (4.90, 5.80) &,#

<1.00 × 10−3

7.37 (5.60, 8.49)

5.32 (5.07, 5.78)

4.71 (3.75, 5.34)
3.10 (2.47, 3.70)

4.71 (4.06, 5.46)
3.07 (2.44, 3.70)

4.58 (3.94, 5.19)
3.10 (2.76, 3.68)

4.76 (4.18, 5.61)
3.19 (2.65, 3.78)

3.97 × 10−1
3.48 × 10−1

4.59 ± 1.47
1.45 (1.05, 2.17)

1.83 (1.51, 2.10)

1.64 (1.29, 2.04)

1.71 (1.27, 1.98)

1.78 (1.32, 2.13)

3.06 × 10−1

2.60 (1.67, 3.47)

2.29 (1.48, 3.17)

2.50 (1.80, 3.43)

2.17 (1.37, 3.28)

57 (85.07%)

149 (81.42%)

47 (92.16%)

161 (87.98%)

1.06 × 10−1
$,#

10−3

104.87 ± 7.38
68.57 ± 3.84 &,$,#

<1.00 × 10−3
<1.00 × 10−3

7.58 (6.77, 7.87)

5.03 (4.76, 5.36) &,#

<1.00 × 10−3

5.19 ± 0.93
1.52 (1.03, 2.38)

4.59 ± 1.15
1.10 (0.71, 1.97)

5.06 ± 0.92 &,#
0.98 (0.77, 1.44) $,#

7.00 × 10−3
<1.00 × 10−3

1.20 (0.95, 1.50)

1.49 (1.25, 1.70)

1.41 (1.07, 1.66)

1.66 (1.44, 1.89) &,#

<1.00 × 10−3

1.04 × 10−1

2.39 (1.86, 3.02)

2.76 (2.37, 3.26)

2.35 (1.80, 2.96)

2.65 (2.24, 3.19) &,#

<1.00 × 10−3

1.57 × 10−1

35 (48.61%)

36 (32.14%)

17 (34.00%)

31 (18.79%) #

<1.00 × 10−3

$,#

Data are shown as mean ± standard deviation or median (P25 , P75 ); if the continuous variables were normally distributed, the t-test was used to analyze the differences between the groups. Otherwise, the
Kruskal–Wallis test was used. χ2 test: Gender, dyslipidemia; BMI, body mass index; DBP, diastolic blood pressure; FBG, fasting blood glucose; HDC, hypertension and type 2 diabetes mellitus comorbidity; HDL,
high-density lipoprotein cholesterol; HTN, hypertension; LDL, low-density lipoprotein cholesterol; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus; TC, total cholesterol; TG, total triglycerides; P25 ,
the 25th percentile; P75 , the 75th percentile; * p < 0.05 was considered statistical significance; & p < 0.0083 was considered statistical significance between HDC and HTN; $ p < 0.0083 was considered statistical
significance between HDC and T2DM; # p < 0.0083 was considered statistical significance between HDC and Controls.
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3.2. The Association of IgG N-Glycans with HDC
IgG N-glycome composition (i.e., GPs and DGs) was analyzed in all samples. Out of
the total 78 glycan traits, 56 and 62 glycan traits were found to be abnormally distributed
(pKolmogorov–Smirnov < 0.05 and pShapiro–Wilk < 0.05) in the pooled samples from the three
Chinese Muslim ethnic minorities and those from Han Chinese, respectively (Table S3).
The differences of directly measured and derived glycan compositions among HDC, HTN,
T2DM, and healthy controls for the Chinese Muslim ethnic minorities and the Han Chinese, respectively, were shown in Figure 1 and Table S3. We found the increased relative
abundance of GP4 (FA2), GP6 (FA2B), and GP11 (FA2[3]BG1) and the reduced relative
abundance of GP14 (FA2G2), GP18 (FA2G2S1), and GP20 (FA2FG2S1) in the HDC group
compared with the other three health condition groups (i.e., HTN, T2DM, and healthy
individuals), with similar trends in the Chinese Muslim ethnic minorities and the Han
Chinese (Figure 1).
Table S4 and its accompanying Venn Diagrams (Figure 2) displays and illustrates
respectively, the results of the logistic regression analysis of IgG N-glycans after adjustment
for potential confounders (i.e., age, gender, ethnicity, BMI, and dyslipidemia), and shared
and unique IgG glycan features between the different health conditions. Noteworthily,
12 (i.e., 7 in HDC versus HTN, 3 in HDC versus T2DM, and 2 in HDC versus Controls)
and 6 (i.e., 3 in HDC versus HTN, 2 in HDC versus T2DM, and 1 in HDC versus Controls)
IgG N-glycan traits were found to be significantly different between four health condition
groups within the three Chinese Muslim minorities pooled samples and Han Chinese
samples, respectively, after controlling the aforementioned confounders and FDR, in the
HDC pairwise comparison with the three health condition groups (i.e., HDC versus HTN,
HDC versus T2DM, and HDC versus healthy individuals) (Table S4 and Figure 3). To
elaborate further, it was found that within the pooled samples from the three Chinese
Muslim minorities, seven glycan traits (increased relative abundance of GP5 [M5], GP6
[FA2B], and DG54 [BG2n /(FG2n + FBG2n )] as well as reduced relative abundance of
GP16 [FA2G1S1], GP18 [FA2G2S1], DG3 [FGS/(F + FG + FGS)], and DG24 [GP8n ]) were
significant differences between HDC and HTN (p < 0.05). Three glycan traits (increased
relative abundance of GP5 and reduced relative abundance of GP16 and GP18) were
significant differences between HDC and T2DM (p < 0.05). In addition, two glycan traits
(GP5 and GP6), with increased relative abundance, were significantly different between
HDC and healthy controls (p < 0.05).
For the pooling of three Chinese Muslim ethnic minorities, we found that one shared
glycan trait—GP5, containing high mannose glycan (M5) in the HDC, was significantly
higher than those in the other three healthy condition groups (i.e., HTN, T2DM, and healthy
individuals). Additionally, two shared glycan traits (GP16 and GP18), containing corefucosylated galactosylated glycans with sialic acid (FA2G1S1 and FA2G2S1, respectively),
were observed in lower levels in the HDC compared with HTN and T2DM, and a corefucosylated agalactosylated glycan containing bisecting GlcNAc eluting in GP6 (FA2B)
was observed in higher levels in the HDC than those in the HTN and healthy individuals
(Figure 3 and Table S4).
Similarly, for the Han Chinese, in comparisons between HDC and the other three
healthy condition groups (i.e., HTN, T2DM, and healthy controls), one shared glycan trait
(GP20 [FA2FG2S1]) containing core-fucosylated digalactosylated glycan with sialic acid of
reduced relative abundance was of statistical significance. The relative abundance of DG2
(FBGS/(FBG + FBGS)) and DG53 (FG2n /(BG2n + FBG2n )) in the HDC were significantly
higher than those in the HTN. Additionally, the increased relative abundance of GP24
(FA2BG2S2) containing sialylation of fucosylated galactosylated structures with bisecting
GlcNAc was found in the HDC compared with the T2DM (Figure 3 and Table S4).
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T2DM, and healthy controls for the Chinese Muslim ethnic minorities and the Han Chinese, respectively, were shown in Figure 1 and Table S3. We found the increased relative
abundance of GP4 (FA2), GP6 (FA2B), and GP11 (FA2[3]BG1) and the reduced relative
abundance of GP14 (FA2G2), GP18 (FA2G2S1), and GP20 (FA2FG2S1) in the HDC group
compared with the other three health condition groups (i.e., HTN, T2DM, and healthy
19
individuals), with similar trends in the Chinese Muslim ethnic minorities and the8 of
Han
Chinese (Figure 1).
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Table S4 and its accompanying Venn Diagrams (Figure 2) displays and illustrates
respectively, the results of the logistic regression analysis of IgG N-glycans after adjustment for potential confounders (i.e., age, gender, ethnicity, BMI, and dyslipidemia), and
shared and unique IgG glycan features between the different health conditions. Noteworthily, 12 (i.e., 7 in HDC versus HTN, 3 in HDC versus T2DM, and 2 in HDC versus Controls) and 6 (i.e., 3 in HDC versus HTN, 2 in HDC versus T2DM, and 1 in HDC versus
Controls) IgG N-glycan traits were found to be significantly different between four health
condition groups within the three Chinese Muslim minorities pooled samples and Han
Chinese samples, respectively, after controlling the aforementioned confounders and
FDR, in the HDC pairwise comparison with the three health condition groups (i.e., HDC
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For the pooling of three Chinese Muslim ethnic minorities, we found that one shared
glycan trait—GP5, containing high mannose glycan (M5) in the HDC, was significantly
higher than those in the other three healthy condition groups (i.e., HTN, T2DM, and
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3.3. The Comparison of IgG N-Glycans between the Chinese Muslim Ethnic Minorities Pooled
Samples and the Han Chinese Samples
We observed the increased relative abundance of sialylated glycans (i.e., GP24, DG2,
and DG53) in the Han Chinese with HDC (HDC versus HTN or T2DM), while a reduced
trend (i.e., GP16, GP18, and DG3) was presented in the Chinese Muslim ethnic minorities
pooled samples with HDC (HDC versus HTN or T2DM). The HDC-associated changes
in the sialylated glycans showed different trends between the Chinese Muslim ethnic
minorities and the Han Chinese as a consequence of the presence or absence of bisecting
GlcNAc in these sialylated glycans in the different ethnic groups.
Although the logistic regression analyses suggested that directly measured and derived IgG N-glycans between the three Chinese Muslim ethnic minorities and the Han
Chinese in the three pairwise comparison groups (i.e., HDC versus HTN, HDC versus
T2DM, and HDC versus healthy controls) did not share similarities in their results, we
found that their respective results all presented low levels of core-fucosylation and galactosylation (i.e., GP16, GP18, and GP20), as well as high levels of bisecting GlcNAc (i.e., GP6,
DG54, GP24, and DG53) in the three Chinese Muslim ethnic minorities with HDC and also
in the Han Chinese with HDC (Figure 3 and Table S4).
3.4. Development of the Classification Models and Discrimination of HDC
Three types of logistic classification models (i.e., baseline models, glycan-based models,
and combined models) were constructed for distinguishing HDC from HTN, T2DM, and
healthy individuals, and were trained and evaluated by the five-fold cross-validation
procedure and ROC curve analysis (Figure 4 and Table 2). The detailed information on the
covariates included in the logistic classification models was shown in Table 2. Specifically,
in the pooling of three Chinese Muslim ethnic minorities, the AUCs of the glycan-based
models discriminating HDC from HTN and T2DM were 0.678 and 0.715, respectively,
showing limited improved discriminative performance than the baseline models. However,
the AUC of the glycan-based model discriminating HDC from healthy controls was lower
than that of the baseline model (difference between AUCs, 0.093, p = 3.97 × 10−2 ). A similar
trend was observed in the Han Chinese for discriminating HDC from healthy controls
(difference between AUCs, 0.115, p = 9.56 × 10−3 ) (Table S5).
Adding both IgG N-glycan and baseline traits to the combined models, the AUCs of
the combined models differentiating HDC from HTN, T2DM, and healthy controls were
0.717, 0.747, and 0.786 in the pooling of three Chinese Muslim ethnic minorities, and 0.828,
0.689, and 0.901 in the Han Chinese, respectively (Table 2). The AUCs showed modest
improvement in the combined models compared to the baseline models, with increments
of 0.064 (p = 4.18 × 10−2 ) for HDC versus HTN, 0.065 (p = 8.66 × 10−2 ) for HDC versus
T2DM, and 0.015 (p = 2.45 × 10−1 ) for HDC versus healthy controls, in the pooling of three
Chinese Muslim ethnic minorities; and with increments of 0.064 (p = 2.22 × 10−2 ) for HDC
vs. HTN, 0.080 (p = 8.99 × 10−2 ) for HDC vs. T2DM, and 0.030 (p = 2.73 × 10− 1 ) for HDC
vs. healthy controls, in the Han Chinese (Table S5). The discriminative performances of
the combined models were shown to be superior to the baseline models. Although not
all the AUCs of the combined models are statistically different from the baseline models,
the addition of glycan variables into the baseline models can increase the discriminative
power of the models. It suggests that IgG N-glycans could reinforce the discriminative
potential of models. Additionally, all but the combined model discriminating HDC from
HTN (Chinese Muslim ethnic minorities) showed lower prediction error than the baseline
and glycan-based models in five-fold cross-validation (Table 2).

J. Pers. Med. 2021, 11, 614
J. Pers. Med. 2021, 11, x FOR PEER REVIEW

11 of 19
12 of 19

Figure4.
4. ROC
ROC curve
curve illustrated
illustrated the
the performance
performanceof
ofthe
the models
models in
in the
the classification
classificationof
of HDC
HDC from
from HTN,
HTN,T2DM,
T2DM,and
andhealthy
healthy
Figure
individuals
for
the
pooled
samples
from
three
Chinese
northwestern
Muslim
ethnic
minorities
(A)
and
those
from
Han
individuals for the pooled samples from three Chinese northwestern Muslim ethnic minorities (A) and those from Han
Chinese
(B).
Chinese (B). When glycan traits are added into the combined models, the AUCs indicated that the IgG glycan profiles
provide more information reinforcing the baseline models utilizing gender, age, ethnicity, BMI, and dyslipidemia as the
When
glycan
added
into
the 0.065
combined
models,
indicated
that the
covariates (with difference between
2 AUCs
(95%traits
CI) ofare
0.064
(0.002,
0.126),
(−0.009,
0.139), the
andAUCs
0.015 (−
0.011, 0.042)
IgG
glycan
profiles
provide
more
information
reinforcing
the
baseline
models
utilizing
in distinguishing HDC from HTN, T2DM, and healthy controls, respectively, in the pooling of three Chinese Muslim ethnic
gender,
BMI,and
and0.030
dyslipidemia
asrespectively,
the covariates
(with
between
minorities, and of 0.064 (0.008,
0.118), age,
0.080 ethnicity,
(−0.013, 0.172),
(0.003, 0.055),
in the
Han difference
Chinese). AUC,
2 AUCs
(95% CI) of
0.064CI,
(0.002,
0.126),
0.065 (−0.009,
0.139), andand
0.015
(−0.011,
0.042) in
area under the receiver operating
characteristic
curve;
confidence
interval;
HDC, hypertension
type
2 diabetes
distinguishing
HDC
from
HTN,
T2DM,
and
healthy
controls,
respectively,
in
the
pooling
mellitus comorbidity; HTN, hypertension; T2DM, type 2 diabetes mellitus; ROC, receiver operating characteristic curve.

of three Chinese Muslim ethnic minorities, and of 0.064 (0.008, 0.118), 0.080 (−0.013, 0.172),
and 0.030 (0.003, 0.055), respectively, in the Han Chinese).
AUC, area under the receiver operating characteristic curve; CI, confidence interval;
HDC, hypertension and type 2 diabetes mellitus comorbidity; HTN, hypertension; T2DM,
type 2 diabetes mellitus; ROC, receiver operating characteristic curve.
Adding both IgG N-glycan and baseline traits to the combined models, the AUCs of
the combined models differentiating HDC from HTN, T2DM, and healthy controls were
0.717, 0.747, and 0.786 in the pooling of three Chinese Muslim ethnic minorities, and 0.828,
0.689, and 0.901 in the Han Chinese, respectively (Table 2). The AUCs showed modest
improvement in the combined models compared to the baseline models, with increments
of 0.064 (p = 4.18 × 10−2) for HDC versus HTN, 0.065 (p = 8.66 × 10−2) for HDC versus T2DM,
and 0.015 (p = 2.45 × 10−1) for HDC versus healthy controls, in the pooling of three Chinese
Muslim ethnic minorities; and with increments of 0.064 (p = 2.22 × 10−2) for HDC vs. HTN,
0.080 (p = 8.99 × 10−2) for HDC vs. T2DM, and 0.030 (p = 2.73 × 10−1) for HDC vs. healthy
controls, in the Han Chinese (Table S5). The discriminative performances of the combined
models were shown to be superior to the baseline models. Although not all the AUCs of
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Table 2. The discriminative performance of models for HDC in the pooled samples from Chinese Muslim ethnic minorities and the Han Chinese samples.
Type of Model

Pooling of Chinese Muslim Ethnic Minorities
Included Variables of
Model

baseline model
HDC vs. HTN

glycan-based model

combined model

baseline model
HDC vs. T2DM

glycan-based model
combined model

baseline model
HDC vs. Controls

glycan-based model
combined model

Age, gender, ethnicity,
BMI, and dyslipidemia
GP5, GP6, GP16,
DG24, and DG54
Age, gender, ethnicity,
BMI, dyslipidemia,
GP5, GP6, GP16,
DG24, and DG54
Age, gender, ethnicity,
BMI, and dyslipidemia
GP5, GP16, and GP18
Age, gender, ethnicity,
BMI, dyslipidemia,
GP5, GP16, and GP18
Age, gender, ethnicity,
BMI, and dyslipidemia
GP5 and GP6
Age, gender, ethnicity,
BMI, dyslipidemia,
GP5, and GP6

Han Chinese

AUC (95%CI)

p*

Prediction Error

0.653 (0.578, 0.728)

2.15 × 10−4

0.280 ± 0.010

0.678 (0.607, 0.748)

1.70 × 10−5

0.279 ± 0.001

0.717 (0.651, 0.782)

1.52 × 10−7

0.291 ± 0.003

0.682 (0.584, 0.779)

6.60 × 10−5

0.439 ± 0.004

0.715 (0.622, 0.808)

7.35 ×

10−4

0.420 ± 0.002

0.747 (0.656, 0.838)

5.00 × 10−6

0.375 ± 0.010

0.771 (0.709, 0.846)

1.70 × 10−5

0.251 ± 0.002

0.678 (0.606, 0.749)

5.64 × 10−11

0.269 ± 0.002

0.786 (0.727, 0.846)

4.03 × 10−12

0.238 ± 0.010

Included Variables
of Model
Age, gender, BMI,
and dyslipidemia
GP20, DG2, and
DG53
Age, gender, BMI,
dyslipidemia, GP20,
DG2, and DG53
Age, gender, BMI,
and dyslipidemia
GP20 and GP24
Age, gender, BMI,
dyslipidemia, GP20,
and GP24
Age, gender, BMI,
and dyslipidemia
GP20
Age, gender, BMI,
dyslipidemia, and
GP20

AUC (95%CI)

p*

Prediction Error

0.764 (0.686, 0.842)

1.49 × 10−9

0.249 ± 0.003

0.715 (0.637, 0.794)

8.38 × 10−7

0.281 ± 0.005

0.828 (0.761, 0.896)

5.91 × 10−14

0.234 ± 0.008

0.609 (0.508, 0.710)

4.13 × 10−2

0.452 ± 0.001

0.663 (0.567, 0.759)

2.23 ×

10−3

0.442 ± 0.009

0.689 (0.594, 0.783)

4.00 × 10−4

0.426 ± 0.007

0.871 (0.812, 0.931)

9.78 × 10−20

0.143 ± 0.001

0.756 (0.685, 0.826)

4.01 × 10−10

0.203 ± 0.001

0.901 (0.850, 0.951)

1.04 × 10−22

0.138 ± 0.001

AUC, area under the curve; BMI, body mass index; CI, confidence interval; DG, derived glycan; GP, glycan peak; HDC, hypertension and type 2 diabetes mellitus comorbidity; HTN, hypertension; SD, standard
deviation; T2DM, type 2 diabetes mellitus; * p < 0.05 was considered statistical significance; The prediction error of five-fold cross-validation procedure was presented in the form of mean ± SD.
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4. Discussion
To the best of our knowledge, this is the first investigation on the association and
discriminative potential of IgG N-glycan traits in HDC versus HTN, T2DM, and healthy
individuals in the pooling of three Chinese Muslim ethnic minorities (KGZ, TJK, and UIG),
inhabiting the northwestern frontier of China, as well as the Han Chinese population.
HTN and T2DM are common comorbidities that are multifactorial diseases driven by
many common pathogenic factors, including modifiable risk factors (obesity, dyslipidemia,
insulin resistance, endothelial dysfunction, vascular inflammation, atherosclerosis, and
sequential inappropriate activation of renin-angiotensin system, etc.) [3,4], environmental
factors, and genetic predisposition [4,34]. IgG contains complex-type biantennary N-glycan
structures, which activate or inhibit IgG Fcγ receptors (FcγRs) by altering the binding
affinity of IgG, thereby decisively affecting effector functions of IgG [35]. The pro- and
anti-inflammatory actions of IgG are modulated by the specific N-glycan residues including
galactose, fucose, sialic acid, and bisecting GlcNAc [9,36,37]. Cumulative evidence indicates that the alteration of terminal modification in IgG N-glycan plays a vital role in the
anti- or pro-inflammatory process. Previous studies reported that aberrant glycosylation of
IgG (low levels of sialylation and core fucosylation, as well as the high level of bisecting
GlcNAc) have been demonstrated to be involved in a range of specific health conditions
related to HDC, including aging, obesity, HTN, T2DM, dyslipidemia, and metabolic syndrome [13,14,31,32,38–40]. In the present study, the altered IgG N-glycosylation profile
was also observed in the HDC patients, further suggesting that IgG N-glycome patterns
are associated with the progression of inflammatory disorders, such as HDC, via inflammatory signaling. These findings present a situation where the role of IgG glycans in the
pathogenesis of HDC extends beyond just a reflection of changes stemming from the onset
of disease, but rather perhaps has some contribution towards influencing pathogenesis
itself resulting from the altered inflammatory actions of IgG.
In this study, the higher level of GP5 (M5) and GP6 (FA2B), and the lower levels
of GP16 (FA2G1S1) and GP18 (FA2G2S1) were found to be the population-specific IgG
N-glycomic changes with statistical significance (p < 0.05) for the pooled samples from three
Chinese Muslim ethnic minorities with HDC; and the lower level of GP20 (FA2FG2S1) were
observed to be unique to the Han Chinese with HDC. In the pooled samples from the three
Chinese Muslim ethnic minorities, HDC patients presented increased core-fucosylation
with bisecting GlcNAc of IgG (GP6 and DG54), but decreased sialylation (GP16, GP18,
and DG3) and monogalactosylated (GP16) and digalactosylated (GP18) core-fucosylated
glycans without bisecting GlcNAc of IgG, when compared with HTN patients. In comparison with T2DM patients, HDC patients showed decreased galactosylation, sialylation,
and core-fucosylation without bisecting GlcNAc of IgG (GP16 and GP18), but increased
mannose structures of IgG (GP5). Additionally, compared to healthy individuals, HDC
patients presented increased core-fucosylation with bisecting GlcNAc (GP6) and mannose
structures of IgG (GP5). In the Han Chinese, the lower level of core-fucosylated galactosylated glycan containing sialic acid of IgG (GP20) was observed in the HDC compared with
HTN/T2DM/healthy individuals, while sialylated glycans (reduced relative abundance of
GP20 and increased relative abundance of GP24 [FA2BG2S2], DG2 [FBGS/(FBG + FBGS)],
and DG53 [FG2n /(BG2n + FBG2n )]) presented inconsistent trends in HDC patients. Specifically, the common characteristic of these HDC-associated sialylated glycans is the presence
of bisecting N-GlcNAc, and the increase of this structural feature in HDC outweighed the
effects of a decrease in sialylation, which is in agreement with the alterations of sialyation
observed in the study on systemic lupus erythematosus [29].
Fucosylation plays key roles in the function of IgG and highly fucosylated IgG shows
a reduced magnitude of antibody-dependent cellular cytotoxicity (ADCC), which is a result
of IgG-subclass IgG1 binding to each of the different Fc receptors [41]. Bisecting GlcNAc
is the central branch of N-glycans, which is biosynthesized by the glycosyltransferase
GnT-III encoded by the MGAT3 gene [42]. The presence of bisecting GlcNAc in N-glycans
could suppress various terminal modifications (fucosylation, sialylation, and others) of N-
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glycans [42], affecting the structure of glycans exerting noteworthy effects on inflammatory
responses or immune function. IgG carrying glycans with bisecting GlcNAc was reported
to have pronouncedly increased affinity to FcγRIIIa leading to an enhancement in ADCC,
whereas fucosylation without bisecting GlcNAc of IgG can reduce ADCC [37]. Previous
studies showed that such increased fucosylation with bisecting GlcNAc was associated with
T2DM [15]. We also observed similarly increased fucosylation in structures with bisecting
GlcNAc (GP6), and decreased fucosylation in structures without bisecting GlcNAc (GP16,
GP18, and GP20) in the HDC patients, compared with HTN and T2DM patients. The
increased fucosylation in structures with bisecting GlcNAc of IgG N-glycans could lead to
the pro-inflammatory status of the body [37], thereby contributing to the progression of
HTN or T2DM towards HDC. Thus, the present results indicate that the individuals with
higher levels of fucosylated structures with bisecting GlcNAc of IgG may increase the risk
for HDC, and that pathophysiological states of individuals with HDC are conditioned on a
chronic inflammatory process.
The level of galactosylation has an essential impact on the inflammatory activities of
IgG; lack of galactosylation was shown to associate with the pro-inflammatory autoimmune
responses through activation of the complement cascade [43]. The down-regulation of
galactosyltransferase activity in plasma cells and the activation of complement cascades
were identified as potential mechanisms for the changes in IgG galactosylation [43]. As
a modulator of inflammatory activity, high galactosylation of IgG Fc N-glycan promotes
the association of the inhibitory receptor FcγRIIb and the lectin-like receptor dectin-1,
which blocks the pro-inflammatory effector functions of C5aR and CXCR2, and enhances
the anti-inflammatory activity of antigen-specific IgG1 immune complexes [44]. Previous
studies have suggested that the decrease in galactosylation of IgG N-glycans play potential
roles in the development and progression of chronic pro-inflammatory diseases, including
HTN, T2DM, and dementia [14–16,45], which are in agreement with the alterations of
IgG N-glycosylation patterns observed in the HDC patients in the present study. The
decreased IgG galactosylation found in HDC presented a similar pattern found in the
previous studies and thus our finding further supports the hypothesis that a decrease in
galactosylation is a general feature of multiple chronic diseases associated with decreased
anti-inflammatory/immunosuppressive potential of circulating IgG.
Besides fucosylation and galactosylation, sialylation mediates partly the inflammatory
function of IgG. IgG shows different pro- and anti-inflammatory potentials on the basis
of different Fcγ receptors that IgG preferentially binds to, and the affinity of the receptor
depends on the composition of the glycans attached to the 297 asparagine [46]. The
addition of sialic acid to IgG can decrease its affinity for FcγRIII, thereby reducing the
degree of ADCC, converting its function from pro- to anti-inflammatory [47]. In the two
comparison groups (HDC versus HTN, HDC versus T2DM), we observed that patients with
HDC showed a significant decrease in sialylation (GP16, GP18, and GP20), indicating that
sialylation is correlated with HDC through decreasing adaptive pro-inflammatory actions
of IgG. However, sialylation with bisecting GlcNAc showed the reduced relative abundance
in HDC patients, which was consistent with the suppression of core fucosylation expression
due to the presence of bisecting GlcNAc. Bisecting GlcNAc inhibits the biosynthesis and
modification of sialic acid of terminal epitopes in N-glycans, which results in the relative
abundance of sialylation (GP16, GP18, GP20, GP24, DG2, DG3, and DG53) presenting
inconsistent trends in HDC patients. Additionally, we found the decrease of GPs containing
galactosylated sialylated glycan structures (GP16, GP18, and GP20) in HDC patients. Since
terminal sialic acid residues are covalently attached to galactosylated glycans, the decrease
of galactosylated sialylation could be a consequence of a decrease in galactosylation [48],
which could provide a plausible explanation for the phenomenon of the co-directional
changes of sialylation and galactosylation shown in the HDC patients. It is worthwhile to
investigate the potential of the level of sialylation and galactosylation of IgG for monitoring
the progression from HTN or T2DM towards HDC. Thus, future prospective cohort studies
are called for to explore if there is a stepwise decrease trend in levels of sialylation and
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galactosylation of IgG during progression from healthy individuals to HTN or T2DM and
then to HDC.
Among the different Chinese ethnic minorities, the similarities and differences in
the glycosylation patterns were found in both the HTN and T2DM patients, compared
with the HDC patients, suggesting that those individuals who have developed T2DM
or HTN do not show consistent alterations of IgG N-glycans. More work is required on
understanding alterations of IgG N-glycans in HTN or T2DM individuals to see if their
alterations over time show an inclination towards HDC. Such IgG N-glycans profiling will
help to contribute towards developing potential glycan biosignatures for monitoring the
progression from HTN or T2DM towards HDC.
The AUCs of the combined models, based on the glycan traits and the baseline
characteristics, demonstrate higher discriminative performance to help discern between
HDC, HTN, T2DM, and healthy individuals than the models based on either the glycan
traits or the baseline characteristics alone. IgG N-glycan profiles reflect the integrative
effects of genetic, metabolic, and environmental factors, contributing significantly towards
their discriminative potential [11]. Although the addition of glycan traits to the baseline
models did not substantially improve the discrimination in all the combined models,
the glycan based models constructed based on IgG N-glycans alone displayed enough
discrimination power and all the combined models showed improved discrimination
performance. These results suggest that IgG N-glycan profiles may contribute significantly
to much of the combined risk of these characteristics, where dynamic and populationspecific IgG N-glycomic changes can serve as functional effectors of the disease potentially
increasing the diagnostic accuracy for complex diseases. The IgG N-glycosylation profiles
associated with HDC described in this study may thus help to shed light on future studies
investigating their biomarker potential for personalized monitoring and prevention of the
progression from HTN or T2DM towards HDC.
The strength of this study is that we evaluated IgG N-glycomes in relation to HDC and
explored similarities and differences in the IgG N-glycosylation profiles for the first time,
particularly in different Chinese ethnic groups, including the Chinese Muslim minorities.
The alterations of IgG N-glycosylation in HDC patients found in this study suggest a
theoretical foundation and present practical direction for future studies to further elaborate
the association of IgG glycosylation with HDC. These suggestions are, however, built
upon the constraints of this study. Firstly, due to the small sample size of HDC in each
ethnic minority in the present study, it is unfeasible to analyze the association of IgG
N-glycans with HDC in each of the Muslim minorities separately. Consequently, the
same health condition groups from the three Chinese Muslim ethnic minorities were
pooled together for the analysis. Furthermore, the Han subjects included in the study
were not co-resident in the Xinjiang Autonomous Region since the Muslim minorities
were recruited from the isolated rural areas in Xinjiang, where the respective Muslim
minority “exclusively” inhabit for generations without co-resident Han or other ethnic
groups. Additionally, it is difficult to match the Han subjects with the Muslim minorities
in terms of their profile of demographic variables due to the relatively small sample size
of the respective health condition group of the Muslim minorities. To compensate for
the potential impact of unmatched demographic variables on the results, we adjusted
the potential confounding factors in the logistic regression analyses. Thirdly, the casecontrol nature of the present study was not able to provide the information about a
causal relationship between the altered IgG glycosylation and the progression of HDC.
A previous study reported that the polymorphisms at six loci (i.e., FUT8, FUT6/FUT3,
HNF1A, MGAT5, B3GAT1, and SLC9A9) affect plasma levels of N-glycans [49], which could
be used as the instrumental variables for future Mendelian randomization (MR) studies
investigating the causal relationship between the altered IgG glycosylation and HDC.
Fourthly, the information on medical treatment of the patients with HTN and/or T2DM
was not completely collected. Consequently, the potential impact of medical treatment for
HTN and/or T2DM on the associations between HDC and IgG glycans was unable to be
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addressed in this current study. Lastly, only the five-fold cross-validation of the model is
performed, external validation of model performance is still needed in further studies.
In the current study, the IgG N-glycans were analyzed by HILIC-UPLC method, which
is a profiling method for total IgG N-glycosylation. The detailed differences between the
glycosylation profiles of the individual IgG subclasses associated with HDC remain to be
investigated, which would be performed in our coming study. Future prospective studies with larger samples in multiracial populations and/or MR studies examining causal
inference are warranted to validate the potential of IgG N-glycosylation biomarkers for
personalized monitoring and prevention of HDC. Clinical exploitation of IgG N-glycan
biomarkers will be facilitated by the existing broad application in clinical laboratories
of UPLC. This study shows the potential clinical application of N-glycans as dynamic
biomarkers (e.g., of routine diagnostic and prophylactic test for HDC patients). Future longitudinal and prospective studies would provide a better understanding of the transition
from HTN or T2DM to HDC and allow us to generate glycan-based markers for use in
earlier detection of the risk of progression towards HDC. As such, healthy lifestyle intervention and therapeutic decision-making could be delivered timely for the HDC prophylaxis
from the perspectives of predictive, preventive and personalized/precision medicine.
5. Conclusions
This study presents conclusive examples of population-specific N-glycosylation of IgG
associated with HDC in three northwestern Chinese Muslim ethnic minorities the KGZ,
TJK, and UIG, as well as a Han Chinese population, respectively. These findings offer an
opportunity to understand how IgG N-glycosylation profiles may be developed as potential
biomarkers indicative of pro- or anti-inflammatory states shared by HTN, T2DM, and HDC.
Further prospective follow-up studies exploring the onset of HDC using glycomics are
expected to provide a more comprehensive understanding of specific glycomic biomarkers
that may serve as tools for personalized monitoring or to help prevent the progression
from HTN or T2DM towards HDC.
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